The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
In a move reflecting growing confidence in the laboratory analytics sector, Bernstein SocGen Group has resumed coverage of Waters Corp. (WAT) with an 'outperform' rating and a $435 price target, according to reports. Analysts cited Waters' strong Q1 2026 results and raised guidance as key drivers, alongside new product launches and strategic partnerships, including a collaboration with IMU Biosciences.
Sign in to access this content
Sign InThe positive assessment comes amid rising demand for advanced analytical equipment in the biotech sector. Bernstein's $435 target represents roughly 15% upside from the stock's last close at $376.89 (close June 25, 2026), per market data. Waters competes with Agilent and Thermo Fisher in a market characterized by steady growth.
Near-term, the focus remains on Waters' ability to sustain its product launch momentum and expand partnerships. The current price leaves room for upside toward the stated target, but investors will watch Q2 results to confirm continued improvement. Any developments in the IMU Biosciences collaboration could provide an additional catalyst for the stock.